What Causes Hyperkalemia?
Discussion Potassium (K+) is an alkali metal (Group 1 of periodic table with Hydrogen, Lithium and Sodium) with an anatomic number of 19. Its chemical symbol K, comes from the medieval Latin, kalium which means potash (mainly potassium carbonate or potassium hydroxide), the substance it was first isolated from. Potassium is an important cation and it mainly resides in the intracellular fluid with only a small amount in the extracellular fluid. Potassium regulates cell volume, pH and enzyme functions. Hyperkalemia is defined as a potassium level> 5.5 mEq/L in children and> 6.0 mEq/L in newborns. Hyperkalemia increases cellular membrane excitability and can cause significant problems with the myocardium, resulting in potentially lethal dysrhythmias. The problem is that hyperkalemia can be completely asymptomatic for the patient and even on ECG. First ECG changes are peaked T waves occurring around> 5.6 mEq/L. With increased K+ levels, the PR interval prolongs and the QRS complex becomes widened. Physical symptoms due to hyperkalemia include muscle weakness, reduced deep tendon reflexes, and paresthesias. Symptoms of the underlying disease obviously also occur. Hyperkalemia is a medial emergency because of its cardiac problems. Treatment is started if there is electrocardiographic changes or serum K+> 6.0-6.5 mEq/L. K+ levels> 6.0 mEq/L are common in neonates and young children due to pseudohypokalemia (i.e. hemolysis caused by venipuncture or capillary samp...
Publication date: Available online 30 September 2020Source: Journal of Hazardous MaterialsAuthor(s): Anthony Beauvois, Delphine Vantelon, Jacques Jestin, Martine Bouhnik-Le Coz, Charlotte Catrouillet, Valérie Briois, Thomas Bizien, Mélanie Davranche
We describe the most highly recommended generic and disease-specific PRO tools in SCD and discuss the challenges of incorporating them in clinical practice. EXPERT OPINION: PRO measures are essential to incorporate into SCD clinical trials either as primary or secondary outcomes. The use of PRO measures in SCD facilitates a patient-centered approach, which is likely to lead to improved outcomes. Significant challenges remain in adapting PRO tools to routine clinical use and in developing countries. PMID: 33034214 [PubMed - as supplied by publisher]
Authors: Musio F Abstract INTRODUCTION: Anemia has and will continue to be a central theme in medicine particularly as clinicians are treating a burgeoning population of complex multi-organ system processes. As a result of multiple randomized controlled trials (RCTs), meta-analyses, and societal recommendations overly restrictive paradigms and under-administration of erythropoiesis stimulating agents (ESAs) have likely been followed by clinicians among all specialties. AREAS COVERED: A review of anemia in the context of chronic kidney disease, hematologic malignancies and cancer is presented with focus on the e...
Authors: Bergland OU, Søraas CL, Larstorp ACK, Halvorsen LV, Hjørnholm U, Hoffman P, Høieggen A, Fadl Elmula FEM Abstract PURPOSE: The blood pressure (BP) lowering effect of renal sympathetic denervation (RDN) in treatment-resistant hypertension shows variation amongst the existing randomised studies. The long-term efficacy and safety of RDN require further investigation. For the first time, we report BP changes and safety up to 7 years after RDN, compared to drug adjustment in the randomised Oslo RDN study. MATERIALS AND METHODS: Patients with treatment-resistant hypertension, defined...
Authors: Zhang W, Xu JZ, Lu XH, Li H, Wang D, Wang JG Abstract PURPOSE: We hypothesise that dietary sodium intake interacts with serum uric acid to influence blood pressure (BP) in children and adolescents. In the present study, we investigated ambulatory BP in relation to hyperuricaemia, dietary sodium intake and their interaction in children and adolescents with hypertension. MATERIALS AND METHODS: A total of 616 study participants were 10-24 years old and had primary hypertension diagnosed after admission in a specialised inpatient ward. Ambulatory BP monitoring was performed during hospitalisat...
Publication date: Available online 9 October 2020Source: Mutation Research/Reviews in Mutation ResearchAuthor(s): Klaudia Kulczynska-Figurny, James J. Bieker, Miroslawa Siatecka
Publication date: Available online 10 October 2020Source: American Journal of Kidney DiseasesAuthor(s): Ibironke W. Apata, Sarah Kabbani, Alicia M. Neu, Tamara M. Kear, Erika M.C. D’Agata, David J. Levenson, Alan S. Kliger, Lauri A. Hicks, Priti R. Patel, authors constitute the ASN and CDC Antibiotic Stewardship White Paper Writing Group
CONCLUSIONS: Xyloglucan/gelose plus ORS was effective and safe in treating acute diarrhea in children. PMID: 33028102 [PubMed - as supplied by publisher]
Publication date: Available online 10 October 2020Source: Journal of Vascular Surgery: Venous and Lymphatic DisordersAuthor(s): N.G. Shah, B.C. Wible, J.A. Paulisi, M. Zaki, P. Lamparello, A. Sista, M. Sadek, G.R. Jacobowitz, T.S. Maldonado
Publication date: Available online 10 October 2020Source: European Journal of Surgical OncologyAuthor(s): Tetsutaro Miyoshi, Satoshi Yamaguchi, Hiroshi Fujimoto, Shigeru Yoshioka, Masayuki Shiobara, Kazuo Wakatsuki, Kosuke Suda, Kotaro Miyazawa, Toshiaki Aida, Yoshihiro Watanabe, Masayuki Ohtsuka
More News: Acid Reflux | Anemia | Bananas | Beta-Blockers | Blood Transusion | Burns | Calcium | Cardiology | Chemistry | Chemotherapy | Children | Chronic Pain | Congenital Adrenal Hyperplasia | Congestive Heart Failure | Contracts | Cough | Databases & Libraries | Diabetes | Dialysis | Electrocardiogram | Emergency Medicine | Endocrinology | Furosemide | Gastroesophageal Reflux Disease | GERD | Heart | Heart Failure | Hemodialysis | Hypertension | Insulin | Intensive Care | Internet | Laboratory Medicine | Learning | Lithium | Pain | Pain Management | Pediatrics | Peritoneal Dialysis | Potassium | Renal Failure | Respiratory Medicine | Rhabdomyolysis | Sickle Cell Anemia | Sodium | Sports Medicine | Thrombosis | Universities & Medical Training | Urology & Nephrology | Wikis